Defining pharmacokinetics for individual patient dosimetry in routine radiopeptide and radioimmunotherapy of cancer: Australian experience

Current Pharmaceutical Design

Volumn 15, Issue 9, 2009, Pages 966-982

  Turner, J Harvey ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Lutetium 177; Radionuclide dosimetry; Radiopharmaceutical pharmacodynamics; Rhenium 188; Therapeutic nuclear oncology

Indexed keywords

ANGIOPEPTIN; ANTINEOPLASTIC AGENT; BIOTIN RE 188; CAPECITABINE; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEMOBESIN RE 188; DEXAMETHASONE; DOXORUBICIN; ETIDRONIC ACID RE 188; ETOPOSIDE; IBRITUMOMAB TIUXETAN; IBRITUMOMAB TIUXETAN IN 111; IFOSFAMIDE; IODINATED POPPYSEED OIL RE 188; LEXIDRONAM SAMARIUM SM 153; OCTREOTATE LU 177; OCTREOTHER; OCTREOTIDE; PASIREOTIDE; PREDNISOLONE; RADIOPHARMACEUTICAL AGENT; RITUXIMAB; RITUXIMAB I 131; SOMATULINE AG; TEMOZOLOMIDE; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; RADIOISOTOPE;

ACUTE LEUKEMIA; AUSTRALIA; B CELL LYMPHOMA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BONE MARROW TRANSPLANTATION; BONE METASTASIS; BONE PAIN; BRAIN HEMORRHAGE; BREAST CANCER; CANCER STEM CELL; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; DOSIMETRY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG UPTAKE; DRUG URINE LEVEL; FOLLICULAR LYMPHOMA; HUMAN; LARGE CELL LYMPHOMA; LIVER CELL CARCINOMA; LIVER METASTASIS; LYMPHOMA; MEDICAL ETHICS; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUROENDOCRINE TUMOR; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RADIATION ABSORPTION; RADIATION DOSE; RADIOIMMUNOTHERAPY; RECURRENT CANCER; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOLID TUMOR; THROMBOCYTOPENIA; WHOLE BODY RADIATION; ANIMAL; CHEMISTRY; ISOTOPE LABELING; METHODOLOGY; NEOPLASM;

ANIMALS; AUSTRALIA; CLINICAL TRIALS AS TOPIC; HUMANS; ISOTOPE LABELING; NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE;

EID: 65549154415     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787582020     Document Type: Review

References (48)

1. Turner JH and Claringbold PG. A Phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose Samarium-153 ethylenediaminetetramethylene phosphonate. Eur J Cancer 1991; 27: 1084-6.
2. Turner JH, Martindale AA, Sorby P, Hetherington EL, Fleay RF, Hoffman RF, et al. Samarium-153 EDTMP therapy of disseminated skeletal metastasis. Eur J Nucl Med 1989; 15: 784-95.
3. Turner JH, Claringbold PG, Hetherington EL, Sorby P, Martindale A. A Phase I Study of Samarium-153 Ethylenediaminetetramethylene Phosphonate Therapy for Disseminated Skeletal Metastases. J Clin Oncol 1989; 17(12) 1926-31.
4. Sinzinger H, Palumbo B, Granegger S, Kratzik C, Palumbo R, Hiltunen J. Repeated low-dose Sm-153 EDTMP therapy using the Vienna protocol is effective in pain palliation and lesion regression. J Nucl Med 2008; 49 (Supplement 1): 369P.
5. Palmedo H, Manka-Waluch A, Albers P, Schmidt-Wolf IGH, Reinhardt M, Ezziddin S, Joe A, et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: Randomized phase II trial with the new, high-energy radiopharmaceutical Rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol 2003; 21: 2869-75.
6. 131I-anti-B1 (anti-CD20) antibody. N Engl J Med 1993; 329: 459-65.
7. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352: 441-9.
8. 131I-tositumuomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96: 1259-66.
9. Czuczman M, Grillo-Lopez AJ, LoBuglio A et al. Patients with low-grade NHL treated with rituximab + CHOP experience prolonged clinical and molecular remission. Blood 2003; 102(Suppl): 411a. abstract.
10. 131I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkins lymphoma. Eur J Nucl Med 2002; 29: 1276.
11. 131I-anti CD 20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: A phase II clinical trial of a non-myeloablative dose regimen of chimeric rituximab radiolabelled in a hospital. Cancer Biother Radiopharmaceut 2003; 18(4): 513-24.
12. 131I-rituximab in clinical practice: 8 year single institution experience of 129 consecutive patients. Ann Oncol 2008; 19(Suppl iv): 89 abstr 015.
13. Leahy MF, Seymour JF, Hicks RJ, Turner JH. Multicenter Phase II clinical study of Iodine-131 rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkins lymphoma. J Clin Oncol 2006; 24: 4418-25.
14. 131I-anti CD 20 rituximab radioimmunotherapy of non-Hodgkins lymphoma. Eur J Nuclear Med Mol Imaging 2005; 32(4): 458-69.
15. 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkins lymphoma: combined data from four clinical trials. J Nucl Med 2003; 44: 465-74.
16. 111In-ibritumomab pre-treatment imaging. J Nucl Med (2008); 49: 1809-12.
17. Juweid ME. Radioimmunotherapy of B-cell non-Hodgkins lymphoma: from clinical trials to clinical practice. J Nucl Med 2002; 43: 1507-29.
18. Morschhauser F, Illidge T, Huglo D, Martinelli G, Paganelli G, Zinzani PL, et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 2007; 110(1): 54-8.
19. 131I-Tositumomab in Clinical Practice. J Nucl Med 2007; 48(11): 1767-76.
20. 131I-rituximab: the Initial Study. Ann Oncol 2008; 19: Sup 4 420.
21. Bishton MJ, Leahy MF, Hicks RJ, Turner JH, McQuillan AD, Seymour JF. Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin's lymphoma who had previously responded to iodine-131-rituximab. Ann Oncol 2008; 19: 1629-33.
22. Leahy MF, McQuillan AD, Turner JH. Radioimmunotherapy with 131I-rituximab for relapsed diffuse large B cell lymphoma: A Phase II Study preliminary report. Ann Oncol 2008; (Suppl 4): 465.
23. 131I-tositumomab (anti-CD 20) radioimmunotherapy for non-Hodgkin's lymphoma: Adjusting radiation absorbed dose to actual organ volumes. J Nucl Med 2004; 45: 1059-64.
24. Wessels BW, Bolck WE, Bouchet LG, Breitz HB, Denardo GL, Meredith RF, et al. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison. J Nucl Med 2004; 45(10): 1725-33.
25. Shen S, DeNardo GL, Sgouros G, O'Donnell RT, DeNardo SJ. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med 1999; 40(12): 2102-6.
26. 131I-Anti CD-20 Rituximab Radioimmunotherapy of Non-Hodgkins Lymphoma and its influence on dosimetry assessment (In Preparation)
27. Gopal AK, Press OW, Wilbur SM, Maloney DG, Pagel J. Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood 2008; 112(3): 830-5.
28. 188Re-lipiodol: Preclinical studies and preliminary therapeutic evaluation in patients with unresectable hepatocellular carcinoma. Nuclear Medicine Communications 2004; 25(7): 691-9.
29. Padhy AK, Dondi M. A Report on the Implementation Aspects of the International Atomic Energy Agency's First Doctoral Coordinated research Project, "Management of Liver Cancer Using Radionuclide Methods With Special Emphasis on Trans-Arterial. Radio-conjugate therapy and internal dosimetry. Semin Nucl Med 2008; 38(2): S5-S12.
30. Janson T, et al. Treatment with high dose [(111) In-DTPA-D-PHE1]-octreotide in patients with neuroendocrine tumors - evaluation of therapeutic and toxic effects. Acta Oncol 1999; 38(3): 373-7.
31. Valkema R, Pauwels S, Kvols LK, Barone R, Jamar F, Bakker WH, et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3] octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2006; 36: 147-56.
32. 3] Octreotate: Toxicity, Efficacy, and Survival. J Clin Oncol 2008; 26(13): 2124-30.
33. Baum RP, Wehrmann C. Zachert C, Mundschenk J, Prasad V, Wortmann R, et al. 5-Year follow-up of peptide receptor radionuclide therapy (PRRT) in 379 patients with progressive somatostatin receptor positive neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007; 34(Suppl 2): S220.
34. 90Y-labeled somatostatin analogs. J Nucl Med 2005; 46(Suppl 1): 92S-8S.
35. Wessels BW, Konijnenberg MW, Dale RG, Breitz HB, Cremonesi M, Meredith RF. MIRD Pamphlet No. 20: The effect of model assumptions on kidney dosimetry and response-implications for radionuclide therapy. J Nucl Med 2008; 49: 1884-99.
36. 177Lu-octreotate/capecitabine therapy of disseminated neuroendocrine tumours. ESMO 2008; 19(Suppl viii): 1067 abstr 509.
37. Strosberg JR, Choi J, Gardner N, Kvols L. First-line treatment of metastatic pancreatic endocrine carcinomas with capecitabine and temozolomide. J Clin Oncol 2008; (Suppl): Abstr 4612.
38. Kvols L, Glusman JE, Hahn EA, Wang E, Oberg L, Darby B, et al. The effects of pasireotide (SOM230) on health-related quality of life in patients with metastatic carcinoid tumors refractory of resistant to octretide LAR. J Clin Oncol 2007; ASCO Annual Meeting Proceedings Part 1. Vol 25, No. 18S (June 20 Supplement), 4558.
39. Wiebe LI. Comparative evaluation of therapeutic radiopharmaceuticals. International Atomic Energy Agency, Vienna: IAEA; 2007. J Nucl Med 2008; 49: 1900.
40. 2-ANT, a somatostatin antagonist for PET imaging of somatostatin receptor-positive tumors. J Nucl Med 2008; 49: 1819-27.
41. Cui Y, Zhang X-P, Sun Y-S, Tang L, Shen L. Apparent diffusion coefficient: Potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 2008; 248: 894-900.
42. 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med 2006; 47: 1144-52.
43. Cescato R, Maina T, Nock B, Nikolopoulou A, Charalambidis D, Piccand V, et al. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med 2008; 49(2): 318-26.
44. Sakahara H, Saga T. Avidin-biotin system for delivery of diagnostic agents. Adv Drug Deliv Rev 1999; 37(1-3): 89-101.
45. Boman BM, Wicha MS. Cancer stem cells: A step toward the cure. J Clin Oncol 2008; 26: 2795-9.
46. Jacobson-Kram D, Mills G. Leveraging exploratory investigational new drug studies to accelerate drug development. Clin Cancer Res 2008; 14(12): 3670-4.
47. Neglia D, Rimoldi O, Kaufmann PA, Camici PG. Radionuclide PET and PET/CT in coronary artery disease. Curr Pharm Des 2008; 14(18): 1798-814.
48. Ruiz-Garcia A, Bermejo M, Moss A, Casabo VG. Pharmacokinetics in drug discovery. J Pharm Sci 2008; 97(2): 654-90.